CD274 and non-small cell lung carcinoma: On October 15, 2021, the FDA approved adjuvant atezolizumab following resection and platinum-based chemotherapy for patients with stage II–IIIA NSCLC and ≥ 1% PD-L1 expression in tumor cells; furthermore, the Ventana PD-L1 (SP263) assay was approved as a companion diagnostic device [25].